INNO-GENE S.A. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.7 PLN | -5.56% |
|
-5.29% | -22.73% |
| 14/02 | Inno-Gene S.A. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023 | CI |
| 14/02 | Inno-Gene S.A. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
| Sales 2021 | 29.88M 7.39M 617M | Sales 2022 | 300K 74.18K 6.19M | Capitalization | 35.12M 8.68M 725M |
|---|---|---|---|---|---|
| Net income 2021 | 6M 1.48M 124M | Net income 2022 | -1M -247K -20.63M | EV / Sales 2021 | 1.65 x |
| Net cash position 2021 | 5.4M 1.34M 112M | Net Debt 2022 | 3.98M 983K 82.04M | EV / Sales 2022 | 130 x |
| P/E ratio 2021 |
8.91
x | P/E ratio 2022 |
-17.6
x | Employees | 10 |
| Yield 2021 * |
-
| Yield 2022 |
-
| Free-Float | 58.81% |
More Fundamentals
* Assessed data
More news
| 1 day | -5.56% | ||
| 1 week | -5.29% | ||
| 3 months | -37.04% | ||
| 6 months | -50.00% | ||
| Current year | -22.73% |
1 week
1.70
1.80
1 month
1.661.99
Current year
1.653.01
1 year
1.656.10
3 years
1.6518.90
5 years
1.4598.80
10 years
0.8898.80
| Managers | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | - | 01/10/01 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | - | - | |
| Chairman | - | 01/16/01 | |
Marcin Golebicki
BRD | Director/Board Member | - | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26/24/26 | 1.7 | -5.56% | 6,976 |
| 25/24/25 | 1.8 | +4.65% | 3,505 |
| 24/24/24 | 1.72 | -4.44% | 4,991 |
| 23/24/23 | 1.8 | +0.28% | 1,370 |
| 22/24/22 | 1.795 | 0.00% | 3,752 |
End-of-day quote Warsaw S.E., April 26, 2024
More quotes
Inno-Gene SA is a Poland-based holding company engaged in management of a portfolio of companies active in life-science sector through the technology, research and development. Inno-Gene SA's portfolio comprises of Centrum Badan DNA Sp. z o.o., a company that provides services in the field of genetic medical diagnostics, including microbiological diagnosis of infection and the suitability of human congenital diseases using tests performed on DNA microarray technology. On March 22, 2013, the Company established a new subsidiary, Centrum Edukacji Bio-Medycznej Sp. z o.o. On April 11, 2013, the Company established two new indirect subsidiaries, Genomix Sp. z o.o. and Madgenetix Sp. z o.o. In addition, it operates through VitainSillica Sp z o o.
| 1st Jan change | Capi. | |
|---|---|---|
| -22.73% | 2.6M | |
| -19.23% | 10.82B | |
| +48.09% | 3.25B | |
| -32.79% | 2.11B | |
| -17.21% | 2.08B | |
| -27.08% | 1.48B | |
| +20.21% | 1.02B | |
| -4.37% | 733M | |
| -34.76% | 391M | |
| -44.61% | 383M |
- Stock Market
- Equities
- IGN Stock
